MCLA-129 + osimertinib

MCLA-129 + osimertinib is a combination therapy under investigation for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations or MET alterations. MCLA-129 is a glycoengineered, Fc-enhanced, common light chain bispecific human IgG1 Biclonics® antibody that targets both the epidermal growth factor receptor (EGFR) and c-MET receptor tyrosine kinases. It inhibits ligand-induced dimerization and phosphorylation of EGFR and c-MET, blocks downstream signaling pathways critical for tumor growth and survival, and promotes immune-mediated tumor cell killing via enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Osimertinib is an oral third-generation small molecule tyrosine kinase inhibitor that selectively inhibits mutant forms of EGFR including T790M resistance mutations. The combination aims to overcome resistance mechanisms in NSCLC by dual targeting of EGFR-driven signaling with both direct inhibition by osimertinib and blockade/immune engagement by MCLA-129[1][2][3].

Brand names

Tagrisso (for osimertinib)pamvatamig (for MCLA-129)

Other names

anti-EGFR/c-MET bispecific antibody + osimertinib